{"id":27402,"date":"2026-07-15T16:16:09","date_gmt":"2026-07-15T14:16:09","guid":{"rendered":"https:\/\/evolute-institute.com\/?page_id=27402"},"modified":"2026-07-15T16:17:24","modified_gmt":"2026-07-15T14:17:24","slug":"utvarderingsramverk-for-psilocybin-retreat","status":"publish","type":"page","link":"https:\/\/evolute-institute.com\/sv\/psilocybin-retreat-evaluation-framework\/","title":{"rendered":"Psilocybin Retreat \u2013 Standarder och utv\u00e4rderingsramverk"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\n
\n\n
\n

Evolute Institute · Open Standard · CC BY 4.0<\/p>\n

Professional Standards for Psilocybin Retreats<\/h1>\n

An Evidence-Informed Evaluation Framework for the Netherlands<\/p>\n

\n Authors:<\/strong> Dr. Dmitrij Achelrod (PhD Health Economics, Hamburg & Oxford; MSc Health Policy, London School of Economics) ·\n Christopher Kabakis (M.Sc., Affiliate Professor, ESCP Europe Business School)
\n Maintained by:<\/strong> Evolute Institute<\/a> ·\n License: CC BY 4.0<\/a> ·\n Last reviewed: 10 July 2026 · Version 2.0-review-draft\n <\/p>\n <\/header>\n\n

\n

Important:<\/strong> This framework is a decision aid, not medical or legal advice and not a substitute for consultation with an independent clinician.<\/p>\n <\/div>\n\n

\n

Executive Overview<\/h2>\n

Psilocybin retreats differ substantially in screening, medication policy, staffing, emergency readiness, ethical safeguards, product transparency, and follow-up. Recent studies of publicly advertised psychedelic retreats found a large and diverse international industry, limited public disclosure, and substantial variation in reported safety practices, such as medication washout practices or medical supervision (Neitzke-Spruill et al., 2025; McGuire et al., 2026).<\/p>\n

Clinical psilocybin research shows that serious adverse events are uncommon in carefully screened and closely supervised studies, but transient anxiety, headache, nausea, fatigue, and increases in blood pressure are common enough to require competent monitoring. Trial findings should not be generalized automatically to commercial retreats, where participant selection, product potency, staffing, documentation, and follow-up may differ materially (Hinkle et al., 2024; Yerubandi et al., 2024; Freitas et al., 2025; Bukovsky et al., 2025; Marinis et al., 2025).<\/p>\n

The framework evaluates ten domains across three phases<\/strong>:<\/p>\n

    \n
  1. Medical and psychiatric screening<\/li>\n
  2. Preparation and informed consent<\/li>\n
  3. Ethics, accountability, and participant rights<\/li>\n
  4. Group design and admission process<\/li>\n
  5. Facilitator competence and staffing<\/li>\n
  6. On-site safety and emergency response<\/li>\n
  7. Facilitation model, claims, and epistemic integrity<\/li>\n
  8. Legal, substance, and physical-setting transparency<\/li>\n
  9. Integration, follow-up, and clinical escalation<\/li>\n
  10. Community and alumni support<\/li>\n <\/ol>\n\n
    \n
    \n

    Phase 1 — Before the Retreat<\/h3>\n

    What a provider does before you arrive determines who is admitted and what safety infrastructure exists if something goes wrong.<\/p>\n

      \n
    1. Medical and Psychiatric Screening<\/strong><\/li>\n
    2. Preparation and Informed Consent<\/strong><\/li>\n
    3. Ethics, Accountability and Participant Rights<\/strong><\/li>\n
    4. Group Design and Admission Process<\/strong><\/li>\n <\/ol>\n <\/div>\n
      \n

      Phase 2 — During the Retreat<\/h3>\n

      On-site infrastructure and facilitation quality during the acute psilocybin experience.<\/p>\n

        \n
      1. Facilitator Competence and Staffing<\/strong><\/li>\n
      2. On-Site Safety and Emergency Response<\/strong><\/li>\n
      3. Facilitation Model and Epistemic Integrity<\/strong><\/li>\n
      4. Legal, Substance and Setting Transparency<\/strong><\/li>\n <\/ol>\n <\/div>\n
        \n

        Phase 3 — After the Retreat<\/h3>\n

        Integration and community determine whether the experience produces lasting change or fades without adequate support.<\/p>\n

          \n
        1. Integration, Follow-Up and Clinical Escalation<\/strong><\/li>\n
        2. Community and Alumni Support<\/strong><\/li>\n <\/ol>\n <\/div>\n <\/div>\n

          Each domain carries its own evidence label<\/strong>, decision outcome<\/strong>, and standards tier<\/strong> — explained below — so a claim can be checked, not just read.<\/p>\n <\/section>\n\n

          \n

          How to Read the Evidence<\/h2>\n

          Standards in this document carry one of three evidence labels.<\/p>\n \n \n \n \n \n
          Direct<\/td>\n Evidence comes from retreat, community-service, or closely comparable group-delivery settings. Examples: retreat landscape studies; a Dutch truffle-retreat integration study; group-retreat trials.<\/span><\/td>\n <\/tr>\n
          Transferred<\/td>\n Evidence comes from controlled trials, naturalistic use, pharmacology, psychotherapy, or harm-reduction research and is applied cautiously to retreats. Examples: cardiovascular effects; medication interactions; set and setting; adverse-event reviews.<\/span><\/td>\n <\/tr>\n
          Operational<\/td>\n A defensible risk-management, ethics, or governance standard that has not been shown in a comparative retreat-outcomes study to reduce harm. Examples: independent complaints process; fixed staff deployment plan; incident review.<\/span><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/section>\n\n
          \n

          How to Make a Decision<\/h2>\n \n \n \n \n \n
          STOP<\/td>\n A material safety, consent, legal, or accountability problem is present. Do not let strengths in other domains compensate for it.<\/td>\n <\/tr>\n
          VERIFY<\/td>\n The provider has not supplied enough specific, documentary evidence. Resolve the uncertainty before paying or attending.<\/td>\n <\/tr>\n
          STRONG PRACTICE<\/td>\n The provider goes beyond baseline safeguards in a way that is transparent, role-appropriate, and evidence-informed.<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/section>\n\n
          \n

          Immediate Stop Signs<\/h2>\n
          \n

          Do not book until independently resolved<\/strong> when any of the following applies:<\/p>\n

            \n
          1. Screening is form-only, no appropriately qualified clinician is accountable for the decision, or the provider accepts everyone who can pay.<\/li>\n
          2. Staff instruct participants to stop, taper, or conceal prescribed medication without the participant's own prescriber or another appropriately qualified clinician directing the plan.<\/li>\n
          3. The provider accepts active psychosis, current mania, active suicidality, severe instability, or inability to provide informed consent into a non-clinical retreat.<\/li>\n
          4. The exact substance, product, dose, booster policy, or use of additional psychoactive substances is unclear.<\/li>\n
          5. No sober person has explicit authority for safety decisions throughout the psychedelic session.<\/li>\n
          6. There is no written emergency plan, no known route to emergency services, or no qualified person able to recognize deterioration and initiate escalation.<\/li>\n
          7. There is no written policy on touch, sexual conduct, confidentiality, dual relationships, or staff-participant boundaries.<\/li>\n
          8. Complaints are handled only by the accused facilitator or by commercial leadership with no independent route or anti-retaliation protection.<\/li>\n
          9. The provider guarantees healing, cure, trauma resolution, spiritual truth, or a specific life outcome.<\/li>\n
          10. The provider markets clinical treatment while being unable to explain the legal and professional basis for providing that treatment in the Netherlands.<\/li>\n
          11. Facilitators are consuming psychedelics during the session without a separate, continuously sober safety team of sufficient capacity.<\/li>\n
          12. Consent documents are unavailable before a non-refundable payment or substantial cancellation penalty.<\/li>\n <\/ol>\n <\/div>\n <\/section>\n\n
            \n

            The Ten Essential Questions<\/h2>\n

            Ask your retreat provider these questions.<\/p>\n \n \n \n
            #<\/th>Domain<\/th>Essential question<\/th><\/tr>\n <\/thead>\n
            \u2460<\/td>Screening<\/td>“Who makes the final participation decision, and what findings lead to decline, deferral, or specialist review?”<\/td><\/tr>\n
            \u2461<\/td>Preparation<\/td>“What live, individualized preparation occurs?”<\/td><\/tr>\n
            \u2462<\/td>Ethics<\/td>“Who is legally accountable, what boundary and touch rules apply, and how can I make a confidential complaint outside the facilitation team?”<\/td><\/tr>\n
            \u2463<\/td>Group design<\/td>“How many participants and staff will be present on my date, and what happens if two or more participants simultaneously need one-to-one support?”<\/td><\/tr>\n
            \u2464<\/td>Facilitation<\/td>“Who will actually be present, what is each person trained and authorized to do, who supervises them, and who remains sober?”<\/td><\/tr>\n
            \u2465<\/td>Emergency response<\/td>“Is there an emergency plan available?”<\/td><\/tr>\n
            \u2466<\/td>Facilitation model<\/td>“Which parts of your model are supported by evidence, theory, spiritual tradition, or practitioner experience?”<\/td><\/tr>\n
            \u2467<\/td>Legal\/product\/setting<\/td>“What exact product is used, what is the current legal basis, how is the batch sourced and stored, and how is dose uncertainty managed?”<\/td><\/tr>\n
            \u2468<\/td>Integration<\/td>“What proactive follow-up is included?”<\/td><\/tr>\n
            \u2469<\/td>Community<\/td>“Is an alumni community available?”<\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/section>\n\n
            \n

            Quick Reference: Identifying Retreats with Strong Standards<\/h2>\n
            \n \n \n \n
            #<\/th>Domain<\/th>⬜ Baseline safeguard<\/th>✅ Strong practice<\/th>🚫 Stop or serious concern<\/th>Evidence status<\/th><\/tr>\n <\/thead>\n
            \u2460<\/td>Screening<\/td>Individual review; accountable clinician with relevant scope; prescriber-led medication decisions<\/td>Role-based medical and psychiatric review; documented decisions and referrals<\/td>Form-only; sales approval; unsupervised washout; accepts acute instability<\/td>Transferred + direct retreat-practice evidence<\/td><\/tr>\n
            \u2461<\/td>Preparation and consent<\/td>Live individual contact; understandable consent before payment; risks, dose, touch, alternatives, withdrawal<\/td>More than one contact; rehearsal of boundaries; personalized contingency plan; facilitator continuity<\/td>Recorded-only; consent after payment; benefits emphasized while risks obscured<\/td>Transferred + ethics evidence<\/td><\/tr>\n
            \u2462<\/td>Ethics and rights<\/td>Named legal entity and team; boundary, privacy, data, complaint, refund, and safeguarding policies<\/td>Independent complaint route; incident transparency<\/td>Anonymous staff; no touch\/sexual-boundary rules; outcome guarantees; complaint conflict<\/td>Ethics consensus + operational governance<\/td><\/tr>\n
            \u2463<\/td>Group design<\/td>Date-specific participant and staff numbers; admission criteria; confidentiality and accessibility plan<\/td>Explicit simultaneous-distress model; backup coverage; equitable inclusion and exclusion review<\/td>First-come admission only; vague maximum number of participants; no plan for disruptive or distressed participants<\/td>Limited direct + group-process evidence<\/td><\/tr>\n
            \u2464<\/td>Facilitation<\/td>Named staff; role and scope matrix; competency and supervision evidence; sober safety lead<\/td>Multidisciplinary team; supervised practice; fatigue\/shift plan; post-retreat review<\/td>Credential by branding alone; all staff altered; no supervision; misleading clinical titles<\/td>Training\/ethics literature; no universal credential standard<\/td><\/tr>\n
            \u2465<\/td>On-site safety<\/td>Written plan; clinically competent sober response; monitoring and emergency access; transfer criteria<\/td>Risk-matched medical presence; drills; equipment and legally governed rescue medicines; incident review<\/td>Telephone-only plan with no local capacity; no escalation thresholds; no discharge criteria<\/td>Transferred + limited direct trial evidence<\/td><\/tr>\n
            \u2466<\/td>Model and claims<\/td>Clear methods, scoped claims, participant autonomy, no imposed interpretation<\/td>Cultural humility; supervision for suggestion and power dynamics<\/td>Cure claims; coercive catharsis; recovered-memory certainty; spiritual or diagnostic imposition<\/td>Transferred + ethics evidence<\/td><\/tr>\n
            \u2467<\/td>Legal\/product\/setting<\/td>Exact product, current legal rationale, dose and booster policy, traceable supply, safe accessible venue<\/td>Batch records\/testing where feasible; documented storage and transport plan<\/td>Unclear substance; undisclosed mixtures; unsafe premises; “legal” used as proof of treatment authorization<\/td>Official legal source + analytical\/setting evidence<\/td><\/tr>\n
            \u2468<\/td>Integration<\/td>Proactive early follow-up; live support; red-flag screening; referral and crisis pathway<\/td>Staged follow-up over weeks; independent clinician option; outcome and adverse-event monitoring<\/td>Single celebratory debrief; no delayed-distress route; staff minimize red flags<\/td>Direct qualitative + transferred evidence<\/td><\/tr>\n
            \u2469<\/td>Community<\/td>Optional, moderated, confidential, easy to leave<\/td>Facilitator oversight; crisis signposting<\/td>Dependency; proselytizing; client recruitment; public disclosure; community presented as care substitute<\/td>Associational + ethics evidence; lower certainty<\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <\/section>\n\n
            \n

            Who Is a Non-Clinical Retreat Appropriate For?<\/h2>\n

            A non-clinical retreat is not a substitute for psychiatric, psychological, or medical treatment. It is most plausibly suited to adults who can consent, are medically and psychologically stable, are not in acute crisis, and can arrange support after the experience. Eligibility must be individualized rather than inferred from marketing categories such as “healthy professional” or from self-assessment alone (Johnson et al., 2008; MacCallum et al., 2022; Hinkle et al., 2024).<\/p>\n

            A non-clinical retreat should ordinarily decline or defer participation when there is active psychosis, current mania, active suicidality, recent severe psychiatric destabilization, inability to consent, pregnancy or breastfeeding, unstable cardiovascular or neurological disease, or current lithium use. Some histories—such as bipolar II disorder, remote or family history of psychosis or bipolar disorder, controlled seizure or cardiovascular disease, or psychiatric polypharmacy—require specialist assessment and may still fall outside a retreat's safe scope (Nayak et al., 2021; Morton et al., 2023; Aaronson et al., 2024; Simonsson et al., 2024; Honk et al., 2024; Freidel et al., 2024; Soto-Angona et al., 2024).<\/p>\n

            Clinical trials involving depression, cancer-related distress, or bipolar II disorder do not establish that people with those conditions can be safely served by a commercial retreat. Trials use protocolized screening, known doses, trained teams, monitoring, documentation, and formal follow-up that may not be present outside research (Goodwin et al., 2022; Aaronson et al., 2024; Back et al., 2026a).<\/p>\n <\/section>\n\n

            Phase 1 — Before the Retreat<\/p>\n\n

            \n

            \u2460 Domain 1 — Medical and Psychiatric Screening<\/h2>\n \n \n
            Why it matters<\/th>Screening identifies people for whom acute physiological effects, medication changes, psychiatric vulnerability, or limited support make a non-clinical retreat unsafe or inappropriate.<\/td><\/tr>\n
            Baseline safeguard<\/th>A named clinician reviews the individual case and makes the final decision. Medication changes are directed by an appropriate prescriber, not by retreat staff.<\/td><\/tr>\n
            Strong practice<\/th>Separate medical and psychiatric expertise is used when indicated; decisions and referrals are documented; the provider publishes its scope and exclusion\/referral policy.<\/td><\/tr>\n
            How to verify<\/th>Ask for the decision-maker's clinical qualification, written screening policy, and medication policy.<\/td><\/tr>\n
            Evidence status<\/th>Transferred<\/strong> from clinical safety, pharmacology, and naturalistic research; direct<\/strong> evidence shows inconsistent retreat screening and medication practices.<\/td><\/tr>\n <\/tbody>\n <\/table>\n\n

            What the screening for a psychedelic retreat should cover<\/h3>\n

            A serious screening process includes:<\/p>\n